CN104203221A - 包含递送剂的组合物及其制备 - Google Patents

包含递送剂的组合物及其制备 Download PDF

Info

Publication number
CN104203221A
CN104203221A CN201380015235.1A CN201380015235A CN104203221A CN 104203221 A CN104203221 A CN 104203221A CN 201380015235 A CN201380015235 A CN 201380015235A CN 104203221 A CN104203221 A CN 104203221A
Authority
CN
China
Prior art keywords
ethoxy
glp
composition
amino
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380015235.1A
Other languages
English (en)
Chinese (zh)
Inventor
T.维赫姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104203221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN202010243609.7A priority Critical patent/CN111494323B/zh
Priority to CN202010243610.XA priority patent/CN111494324B/zh
Publication of CN104203221A publication Critical patent/CN104203221A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380015235.1A 2012-03-22 2013-03-15 包含递送剂的组合物及其制备 Pending CN104203221A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010243609.7A CN111494323B (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备
CN202010243610.XA CN111494324B (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12160742.8 2012-03-22
EP12160742 2012-03-22
US201361748844P 2013-01-04 2013-01-04
US61/748844 2013-01-04
EP13153422.4 2013-01-31
EP13153422 2013-01-31
PCT/EP2013/055363 WO2013139695A1 (en) 2012-03-22 2013-03-15 Compositions comprising a delivery agent and preparation thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202010243609.7A Division CN111494323B (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备
CN202010243610.XA Division CN111494324B (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备

Publications (1)

Publication Number Publication Date
CN104203221A true CN104203221A (zh) 2014-12-10

Family

ID=49221869

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010243609.7A Active CN111494323B (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备
CN201380015235.1A Pending CN104203221A (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备
CN202010243610.XA Active CN111494324B (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010243609.7A Active CN111494323B (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010243610.XA Active CN111494324B (zh) 2012-03-22 2013-03-15 包含递送剂的组合物及其制备

Country Status (11)

Country Link
US (1) US10335369B2 (enExample)
EP (3) EP4331667A3 (enExample)
JP (1) JP6356660B2 (enExample)
CN (3) CN111494323B (enExample)
ES (1) ES2965469T3 (enExample)
HR (1) HRP20231613T1 (enExample)
HU (1) HUE064694T2 (enExample)
PL (2) PL3542790T3 (enExample)
RS (2) RS64942B1 (enExample)
SI (1) SI2827845T1 (enExample)
WO (1) WO2013139695A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883073A (zh) * 2016-12-30 2018-11-23 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
CN111683676A (zh) * 2018-02-02 2020-09-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
CN112153979A (zh) * 2018-05-07 2020-12-29 诺和诺德股份有限公司 包含glp-1激动剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
CN113329810A (zh) * 2019-01-24 2021-08-31 诺和诺德股份有限公司 辊压机和使用辊压机的干法制粒方法
WO2021227146A1 (zh) * 2020-05-14 2021-11-18 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
CN115461044A (zh) * 2020-04-29 2022-12-09 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
WO2023098777A1 (zh) * 2021-12-01 2023-06-08 江苏恒瑞医药股份有限公司 Glp-1和gip受体双重激动剂的药物组合物及其用途

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180425T1 (hr) 2010-12-16 2018-04-20 Novo Nordisk A/S Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
SMT201800491T1 (it) 2012-03-22 2018-11-09 Novo Nordisk As Composizioni di peptidi glp-1 e relativa preparazione
PT2827845T (pt) * 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
ES2688462T3 (es) 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1
CN104173313B (zh) * 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
DK3244878T3 (da) 2015-01-12 2022-10-17 Enteris Biopharma Inc Faste orale sammensætningsformer
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
PE20220486A1 (es) * 2019-08-07 2022-04-04 Novo Nordisk As Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
JP7767264B2 (ja) 2019-09-02 2025-11-11 ノヴォ ノルディスク アー／エス Ｇｌｐ－１ペプチドを含む錠剤を生成するためのプロセス
WO2021043971A1 (en) 2019-09-06 2021-03-11 Novo Nordisk A/S Method and equipment for fractionation of granules for use in pharmaceutical compositions
JP2023502004A (ja) 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
CA3184723A1 (en) * 2020-07-22 2022-01-27 Patrick J. KNERR Glp-1 and gip receptor co-agonists
BR112023000270A2 (pt) 2020-07-22 2023-01-31 Novo Nordisk As Composto, composição farmacêutica, e, peptídeo
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
EP4333814A1 (en) 2021-05-07 2024-03-13 Eli Lilly and Company Erodible tablet
PE20241302A1 (es) * 2021-07-15 2024-06-24 Novo Nordisk As Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107773A2 (en) * 2004-05-06 2005-11-17 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
ES2059366T3 (es) 1986-03-12 1994-11-16 American Cyanamid Co Compuestos macrolidos.
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
ES2301477T3 (es) 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP2004527518A (ja) 2001-03-27 2004-09-09 ランバクシー ラボラトリーズ リミテッド プラバスタチンの安定薬剤組成物
BR0209644A (pt) 2001-05-15 2004-07-06 Warner Lambert Co Processo de compactação para fabricação de uma forma de dosagem de fenitoìna de sódio
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
WO2003045331A2 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
PL372394A1 (en) 2002-02-01 2005-07-25 Pfizer Products Inc. Dry granulated formulations of azithromycin
JP4417113B2 (ja) 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
US20050009748A1 (en) 2003-05-14 2005-01-13 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
AU2004255458B2 (en) 2003-07-11 2007-09-13 Emisphere Technologies, Inc. Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
WO2005058954A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
US8636996B2 (en) 2004-05-06 2014-01-28 Emisphere Technologies, Inc Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
CN1767818A (zh) 2004-05-31 2006-05-03 三亚药品株式会社 含β－内酰胺抗生素的分散片剂及其制备方法
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
ES2755273T3 (es) 2004-12-03 2020-04-22 Merck Sharp & Dohme Formulación farmacéutica de inhibidores de la carboxamida VIH integrasa que contienen una composición de control de la velocidad de liberación
EP1843755B1 (en) 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CA2603105A1 (en) 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
RU2469709C2 (ru) 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007146234A2 (en) 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US9364502B2 (en) 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
ES2498519T3 (es) 2006-09-07 2014-09-24 F. Hoffmann-La Roche Ag Un procedimiento para la fabricación de SNAC (SALCAPROZATO SÓDICO)
PE20080845A1 (es) 2006-09-22 2008-08-13 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
US20100069410A1 (en) 2006-12-01 2010-03-18 Emisphere Technologies Inc. acyclovir formulations
AU2008223108B2 (en) 2007-03-02 2013-10-10 Novartis Ag Oral administration of a calcitonin
EP2182956A2 (en) 2007-08-29 2010-05-12 The Regents of the University of California Salicylanilide modified peptides for use as oral therapeutics
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
AU2009283821B2 (en) 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins
EA029759B1 (ru) * 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20110311621A1 (en) 2010-03-16 2011-12-22 Paul Salama Pharmaceutical compositions and methods of delvery
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
HRP20180425T1 (hr) * 2010-12-16 2018-04-20 Novo Nordisk A/S Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
SMT201800491T1 (it) 2012-03-22 2018-11-09 Novo Nordisk As Composizioni di peptidi glp-1 e relativa preparazione
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
ES2688462T3 (es) 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107773A2 (en) * 2004-05-06 2005-11-17 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RE STEINERT等: "Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects", 《CLINICAL PHARMACOLOGY & THERAPEUTICS》 *
XIAORONG HE等: "Mechanistic Study of the Effect of Roller Compaction and Lubricant on Tablet Mechanical Strength", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883073A (zh) * 2016-12-30 2018-11-23 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
CN108883073B (zh) * 2016-12-30 2021-10-08 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
CN111683676A (zh) * 2018-02-02 2020-09-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
CN112153979A (zh) * 2018-05-07 2020-12-29 诺和诺德股份有限公司 包含glp-1激动剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
CN113329810A (zh) * 2019-01-24 2021-08-31 诺和诺德股份有限公司 辊压机和使用辊压机的干法制粒方法
CN115461044A (zh) * 2020-04-29 2022-12-09 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
WO2021227146A1 (zh) * 2020-05-14 2021-11-18 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
WO2023098777A1 (zh) * 2021-12-01 2023-06-08 江苏恒瑞医药股份有限公司 Glp-1和gip受体双重激动剂的药物组合物及其用途

Also Published As

Publication number Publication date
US10335369B2 (en) 2019-07-02
US20150031606A1 (en) 2015-01-29
EP2827845A1 (en) 2015-01-28
RS64942B1 (sr) 2024-01-31
JP6356660B2 (ja) 2018-07-11
CN111494323A (zh) 2020-08-07
SI2827845T1 (sl) 2019-04-30
RS58636B1 (sr) 2019-05-31
EP4331667A3 (en) 2024-05-08
CN111494324B (zh) 2023-05-16
EP2827845B1 (en) 2018-12-26
EP3542790C0 (en) 2023-09-13
PL3542790T3 (pl) 2024-02-26
CN111494323B (zh) 2023-03-28
CN111494324A (zh) 2020-08-07
HRP20231613T1 (hr) 2024-03-15
EP3542790B1 (en) 2023-09-13
HUE064694T2 (hu) 2024-04-28
EP4331667A2 (en) 2024-03-06
EP3542790A1 (en) 2019-09-25
ES2965469T3 (es) 2024-04-15
WO2013139695A1 (en) 2013-09-26
JP2015515459A (ja) 2015-05-28
PL2827845T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
CN111494323B (zh) 包含递送剂的组合物及其制备
US11759503B2 (en) Compositions of GLP-1 peptides and preparation thereof
US11123296B2 (en) Compositions comprising a delivery agent and preparation thereof
TWI804571B (zh) 包含glp-1促效劑及n-(8-(2-羥苯甲醯基)胺基)辛酸之鹽的固體組成物
JP2016117759A (ja) Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
KR20200013078A (ko) Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Denmark bagsvaerd

Applicant after: Novo Nordisk limited company

Address before: Denmark bagsvaerd

Applicant before: NOVO NORDISK AS

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM:

Free format text: CORRECT: APPLICANT; FROM: NOVO NORDISK A/S (A/S) TO: NOVO NORDISK A/S

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141210